BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 10172482)

  • 1. Pricing and reimbursement of pharmaceuticals in Sweden.
    Jönsson B
    Pharmacoeconomics; 1994; 6 Suppl 1():51-60. PubMed ID: 10172482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
    Davidova J; Praznovcova L; Lundborg CS
    Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pricing and reimbursement of pharmaceuticals in Italy.
    Folino-Gallo P; Montilla S; Bruzzone M; Martini N
    Eur J Health Econ; 2008 Aug; 9(3):305-10. PubMed ID: 18566845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of European pharmaceutical price regulation on generic price competition: a review.
    Puig-Junoy J
    Pharmacoeconomics; 2010; 28(8):649-63. PubMed ID: 20515079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug Policy in Romania.
    Radu CP; Pana BC; Furtunescu FL
    Value Health Reg Issues; 2018 Sep; 16():28-32. PubMed ID: 29704726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New developments in pricing and drug reimbursement in France.
    Pelc A; Castan JP
    Pharmacoeconomics; 1994; 6 Suppl 1():28-35. PubMed ID: 10155583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evolution of Taiwan's National Health Insurance drug reimbursement scheme.
    Hsu JC; Lu CY
    Daru; 2015 Feb; 23(1):15. PubMed ID: 25889754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pricing and reimbursement of pharmaceuticals.
    Towse A
    Pharmacoeconomics; 1994; 6 Suppl 1():36-8. PubMed ID: 10155584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent public policies in The Netherlands to control pharmaceutical pricing and reimbursement.
    Rigter H
    Pharmacoeconomics; 1994; 6 Suppl 1():15-21. PubMed ID: 10155581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does drug price-regulation affect healthcare expenditures?
    Ben-Aharon O; Shavit O; Magnezi R
    Eur J Health Econ; 2017 Sep; 18(7):859-867. PubMed ID: 27696009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pricing and reimbursement of orphan drugs: the need for more transparency.
    Simoens S
    Orphanet J Rare Dis; 2011 Jun; 6():42. PubMed ID: 21682893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug Policy in Bulgaria.
    Dimova A; Rohova M; Atanasova E; Kawalec P; Czok K
    Value Health Reg Issues; 2017 Sep; 13():50-54. PubMed ID: 29073988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost containment interventions introduced on the community drugs schemes in Ireland-evaluation of expenditure trends using a national prescription claims database.
    Usher C; Tilson L; Bennett K; Barry M
    Clin Ther; 2012 Mar; 34(3):632-9. PubMed ID: 22381716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmaceutical reference pricing in Germany: definition of therapeutic groups, price setting through regression procedure and effects].
    Stargardt T; Schreyögg J; Busse R
    Gesundheitswesen; 2005 Jul; 67(7):468-77. PubMed ID: 16103970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do pharmaceutical prices respond to potential patient out-of-pocket expenses?
    Pavenik N
    Rand J Econ; 2002; 33(3):469-87. PubMed ID: 12585303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incentives and pharmaceutical reimbursement reforms in Spain.
    Puig-Junoy J
    Health Policy; 2004 Feb; 67(2):149-65. PubMed ID: 14720633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals.
    Andersson K; Bergström G; Petzold MG; Carlsten A
    Health Policy; 2007 May; 81(2-3):376-84. PubMed ID: 16945449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impacts of cost containment strategies on pharmaceutical expenditures of the National Health Insurance in Taiwan, 1996-2003.
    Lee YC; Yang MC; Huang YT; Liu CH; Chen SB
    Pharmacoeconomics; 2006; 24(9):891-902. PubMed ID: 16942123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.